Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Iobenguane I-131 - Progenics Pharmaceuticals

Drug Profile

Iobenguane I-131 - Progenics Pharmaceuticals

Alternative Names: 131-I-metaiodobenzylguanidine; 131-I-MIGB; 131I-iobenguane - Progenics Pharmaceuticals; 131I-MIBG - Progenics Pharmaceuticals; 3-iodobenzylguanidine-I-123; Azedra; HSA I-131 MIBG; I-131 mIBG; I-131-iobenguane; Iobenguane-I123-injection; Iobenguane-I131; Iobenguane-sulfate; Iodine-123 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131 iobenguane - Progenics Pharmaceuticals; Iodine-131 metaiodobenzylguanidine - Progenics Pharmaceuticals; Iodine-131-metaiodobenzylguanidine; Iodine-I-131-metaiodobenzylguanidine; m-Iodobenzylguanidine-sulfate; Meta-iodobenzylguanidine; Metaiodobenzylguanidine-I-123; Metaiodobenzylguanidine-I-131; Metaiodobenzylguanidine-sulfate; MIBG; MIP-120T; Ultratrace I-131-MIBG; Ultratrace iobenguane I 131; Ultratrace MIBG; Ultratrace-iobenguane-I-131

Latest Information Update: 10 Aug 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer Progenics Pharmaceuticals
  • Class Antineoplastics; Guanidines; Imaging agents; Iodobenzenes; Radiopharmaceutical diagnostics; Small molecules; Sulfates
  • Mechanism of Action Cell death stimulants; Neuron inhibitors; Poly(ADP-ribose) polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • New Molecular Entity No

Highest Development Phases

  • Marketed Neuroendocrine tumours
  • Phase II Neuroblastoma

Most Recent Events

  • 06 Aug 2019 The Centers for Medicare & Medicaid Services approves a new technology add-on payment (NTAP) for iobenguane I-131 for Medicare hospital inpatient cases
  • 20 Jun 2019 Progenics Pharmaceuticals plans a basket study trial for Neuroendocrine tumours (Unresectable/Inoperable, Metastatic disease) in MIBG avid patients in USA and Canada (IV) by end-2019
  • 20 Jun 2019 Progenics Pharmaceuticals reaches alignment with US FDA at the conclusion of a Type B meeting, regarding potential label expansion of iobenguane I-131 in treatment of Neuroendocrine tumours (Inoperable/Unresectable, Metastatic disease) in MIBG avid patients
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top